Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, raised $44 million by offering 5.5 million shares (up from 5.0 million) at $8, as expected. Celladon Corporation plans to list on the NASDAQ under...read more
Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, lowered the proposed deal size for its upcoming IPO on Tuesday. The San Diego, CA-based company now plans to raise $40 million by offering 5.0...read more
Celladon, which is developing novel therapies for the treatment of heart disease, revived its IPO by filing an amended S-1 with the SEC on Wednesday. The company had previously launched a deal to sell 5 million shares at $14 to $16 per share but postponed...read more
US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
Celladon prices upsized IPO at $8
Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, raised $44 million by offering 5.5 million shares (up from 5.0 million) at $8, as expected. Celladon Corporation plans to list on the NASDAQ under...read more
Celladon revises terms, drops IPO price to $8
Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, lowered the proposed deal size for its upcoming IPO on Tuesday. The San Diego, CA-based company now plans to raise $40 million by offering 5.0...read more
Cardiovascular biotech Celladon revives IPO filing, removes original terms
Celladon, which is developing novel therapies for the treatment of heart disease, revived its IPO by filing an amended S-1 with the SEC on Wednesday. The company had previously launched a deal to sell 5 million shares at $14 to $16 per share but postponed...read more